Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Thomson Reuters Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.72 (market cap $4.49B), while Thomson Reuters Corp trades at $89 (market cap $39.64B). The key difference: Thomson Reuters Corp is far larger — about 8.8× ACADIA Pharmaceuticals Inc.'s market cap, and Thomson Reuters Corp pays a 2.89% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | TRI | |
|---|---|---|
Market Cap | $4.49B | $39.64B |
Sector | Health | Industrials |
52-Week High | $28.06 | $214.21 |
52-Week Low | $20.06 | $76.55 |
Enterprise Value | $3.69B | $41.59B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Thomson Reuters (TRI) trades at $90.76, up 1.74% with bullish technical indicators and strong analyst support. The company reported Q1 2026 EPS of $1.23, beating estimates, while revenue reached $7.48B in 2025. Recent corporate actions include a special dividend and reverse stock split. Technical analysis shows resistance near $92 with RSI indicating potential overbought conditions.
Outlook remains positive with a consensus price target of $129.96, though risks include AI implementation challenges and competitive pressures. Revenue growth is steady, but net income margin compression from 39.66% in 2023 to 20.09% in 2025 warrants monitoring. Institutional sentiment is bullish with 51.85% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
